2025

Stergios Moschos, MD, discusses his approach to selecting from the available agents in metastatic melanoma after first-line PD-1 inhibition.

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.
This article is part 1 of a 2-part series from a Case-Based Roundtable event.

Scientists at the Icahn School of Medicine at Mount Sinai have discovered a possible reason why some cases of melanoma—a dangerous form of skin cancer—spread to the brain. Their study, published in Molecular Cell, highlights the role of a group of proteins called the PBAF chromatin remodeling complex in keeping melanoma from getting worse.

Researchers identified key ancestral contributions among patients with high-risk melanoma in a US intergroup phase 3 trial. Most cases genetically clustered with European reference populations, with smaller subsets aligning with admixed American and East Asian ancestries.